Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

NeoPharm, FDA Define Plans For IL13's Phase III Program

Feb. 9, 2004

By Aaron Lorenzo

Nuvelo Adds Dendreon's Heart Product To Thickening Pipeline

Feb. 6, 2004

By Aaron Lorenzo

Nuvelo Adds Dendreon's Heart Product To Thickening Pipeline

Feb. 6, 2004

By Aaron Lorenzo

Caprion Pairs Proteomics-Based Lung Cancer Work With Abbott

Feb. 5, 2004

By Aaron Lorenzo

Caprion Pairs Proteomics-Based Lung Cancer Work With Abbott

Feb. 5, 2004

By Aaron Lorenzo

Liver Drug Developer Metabasis Files Registration For $86M IPO

Feb. 4, 2004

By Aaron Lorenzo

Liver Drug Developer Metabasis Files Registration For $86M IPO

Feb. 4, 2004

By Aaron Lorenzo

Targeted Genetics Adding $25.5M To Cash Via Public Stock Offering

Feb. 3, 2004

By Aaron Lorenzo

Targeted Genetics Adding $25.5M To Cash Via Public Stock Offering

Feb. 3, 2004

By Aaron Lorenzo

Palatin Raises $22.7M For Drug Trials Via Stock, Warrants Sale

Feb. 2, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...